Accueil
Envoyer à un ami
Imprimer
Grand
Petit
Partager
ACTUALITES

Novartis International AG - Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study


- 16 Novembre 2016 modifié le 1 Janvier 1970


Novartis International AG / Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for...

Source : http://www.romandie.com/news/Novartis-Internationa...